Zobrazeno 1 - 3
of 3
pro vyhledávání: '"M A Zambrano Chacon"'
Autor:
R Fernandez-Roblas, Óscar González-Lorenzo, A M Venegas Rodriguez, M A Zambrano Chacon, F Villar-Alvarez, Laura Esteban-Lucía, J Tunon, L Maure-Blesa, A Acena Navarro, Juan Antonio Franco-Peláez, M Gonzalez-Rodriguez, A Devesa-Arbiol, Ana María Pello-Lázaro, P Avila-Barahona, A M Kallmeyer-Mayor
Publikováno v:
European Heart Journal
Background High incidence of cardiovascular events has been described among patients with COVID-19 and since the beginning of the pandemic concerns have been expressed with medical treatments for cardiovascular disease, as they could contribute to th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::845fbf9c45eb60e0ab41d1ff06d72b47
https://doi.org/10.1093/eurheartj/ehab724.3006
https://doi.org/10.1093/eurheartj/ehab724.3006
Autor:
R Fernandez-Roblas, L Maure-Blesa, M Gonzalez-Rodriguez, J A Franco Pelaez, Óscar González-Lorenzo, J Tunon, Ana María Pello-Lázaro, A Devesa-Arbiol, A M Venegas Rodriguez, M A Zambrano Chacon, Borja Ibanez, A Acena Navarro, P Avila-Barahona, Laura Esteban-Lucía, F Villar-Alvarez
Publikováno v:
European Heart Journal. 42
Background On January 2020, the first patient with coronavirus 2 (SARS-CoV-2) was detected in Spain. Since then, 3 280 000 cases have been confirmed and 75.305 people have died. We aimed to clarify the epidemiological and clinical characteristics rel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::89137c4063c23c40108f6f2239865b2d
https://doi.org/10.1093/eurheartj/ehab724.2468
https://doi.org/10.1093/eurheartj/ehab724.2468
Autor:
R Fernandez-Roblas, F Villar-Alvarez, Óscar González-Lorenzo, Laura Esteban-Lucía, M Gonzalez-Rodriguez, P Avila-Barahona, A M Venegas Rodriguez, M A Zambrano Chacon, A Acena Navarro, A M Kallmeyer-Mayor, J Tunon, A Devesa-Arbiol, Juan Antonio Franco-Peláez, L Maure-Blesa, Ana María Pello-Lázaro
Publikováno v:
European Heart Journal. 42
Background Questions emerged about safety renin-angiotensin system (RAS) inhibitors (angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs)) in patients diagnosed with severe acute respiratory syndrome coronavirus-2 (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1ccb3c72ce3be56d27c809246779bc7c
https://doi.org/10.1093/eurheartj/ehab724.2969
https://doi.org/10.1093/eurheartj/ehab724.2969